Department of Medicine and Aging Science, "G. d'Annunzio" University, Chieti, Italy.
Clinical Research Center, Center for Advanced Studies and Technologies (CAST), "G. d'Annunzio" University, Chieti, Italy.
Sci Rep. 2021 Feb 18;11(1):4136. doi: 10.1038/s41598-021-83047-w.
Diabetic retinopathy (DR) is a leading cause of vision loss and disability. Effective management of DR depends on prompt treatment and would benefit from biomarkers for screening and pre-symptomatic detection of retinopathy in diabetic patients. MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression which are released in the bloodstream and may serve as biomarkers. Little is known on circulating miRNAs in patients with type 2 diabetes (T2DM) and DR. Here we show that DR is associated with higher circulating miR-25-3p (P = 0.004) and miR-320b (P = 0.011) and lower levels of miR-495-3p (P < 0.001) in a cohort of patients with T2DM with DR (n = 20), compared with diabetic subjects without DR (n = 10) and healthy individuals (n = 10). These associations persisted significant after adjustment for age, gender, and HbA1c. The circulating levels of these miRNAs correlated with severity of the disease and their concomitant evaluation showed high accuracy for identifying DR (AUROC = 0.93; P < 0.001). Gene ontology analysis of validated targets revealed enrichment in pathways such as regulation of metabolic process (P = 1.5 × 10), of cell response to stress (P = 1.9 × 10), and development of blood vessels (P = 2.7 × 10). Pending external validation, we anticipate that these miRNAs may serve as putative disease biomarkers and highlight novel molecular targets for improving care of patients with diabetic retinopathy.
糖尿病视网膜病变(DR)是视力丧失和残疾的主要原因。DR 的有效管理取决于及时治疗,并且将受益于生物标志物,用于筛选和预测糖尿病患者的视网膜病变。微小 RNA(miRNA)是基因表达的转录后调节剂,它们在血液中释放出来,可能作为生物标志物。关于 2 型糖尿病(T2DM)和 DR 患者的循环 miRNA 知之甚少。在这里,我们显示在患有 DR 的 T2DM 患者队列中(n=20),与没有 DR 的糖尿病患者(n=10)和健康个体(n=10)相比,DR 与更高的循环 miR-25-3p(P=0.004)和 miR-320b(P=0.011)水平以及更低的 miR-495-3p 水平相关(P<0.001)。这些关联在调整年龄、性别和 HbA1c 后仍然显著。这些 miRNA 的循环水平与疾病的严重程度相关,它们的同时评估显示出识别 DR 的高准确性(AUROC=0.93;P<0.001)。经过验证的靶基因的基因本体分析显示,代谢过程调节(P=1.5×10)、细胞对应激的反应(P=1.9×10)和血管发育(P=2.7×10)等途径富集。在等待外部验证的情况下,我们预计这些 miRNA 可能作为潜在的疾病生物标志物,并突出用于改善糖尿病视网膜病变患者护理的新分子靶标。